International Journal of ADVANCED RESEARCH & INNOVATIONS

Volume 14, Issue-12
December, 2024, P23
ISSN: 2319-9253

CAUSAL ARTIFICIAL INTELLIGENCE IN ONCOLOGY: ENHANCING EXPLAINABILITY AND CLINICAL DECISION-MAKING IN PRECISION MEDICINE

[#1]**Dr. Raghavendra Joshi**, Professor, Department of Radiation Oncology,
SDM College of Medical Sciences and Hospital Dharwad, India
Raghav.joshi76@gmail.com

Abstract: Causal artificial intelligence (AI) is emerging as a transformative paradigm in precision oncology by enabling computational systems to move beyond correlation-based prediction toward causal reasoning that supports transparent, reliable, and clinically actionable decision-making. Conventional machine learning and deep learning models have achieved remarkable success in cancer diagnosis, prognosis, and therapeutic prediction; however, many remain limited by their inability to distinguish causal relationships from statistical associations, thereby reducing interpretability, generalizability, and clinical trust. Recent advances in causal inference, foundation AI models, multimodal transformer architectures, graph neural networks, structural causal models, Bayesian networks, reinforcement learning, and generative artificial intelligence have enabled integration of radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory biomarkers, circulating tumor DNA, wearable physiological monitoring, electronic health records, and longitudinal clinical outcomes into explainable computational frameworks. These intelligent systems support early cancer detection, molecular characterization, biomarker discovery, prognostic prediction, treatment optimization, immunotherapy selection, digital twin simulation, adaptive disease monitoring, and evidence-based clinical decision support through causal reasoning rather than correlation alone. Emerging technologies including multimodal large language models, federated learning, retrieval-augmented generation, explainable artificial intelligence, and agentic AI further strengthen causal oncology by enabling collaborative, privacy-preserving, transparent, and continuously adaptive biomedical intelligence. Despite substantial technological progress, important scientific, technical, ethical, and regulatory challenges remain regarding causal model validation, multimodal data harmonization, computational scalability, interoperability, cybersecurity, clinical validation, and equitable implementation. This review provides a comprehensive overview of causal artificial intelligence in oncology, emphasizing its role in enhancing explainability and clinical decision-making for precision medicine.[1]

Keywords: *Causal artificial intelligence, Precision oncology, Explainable AI, Foundation models, Causal inference, Clinical decision support, Computational oncology, Personalized medicine, Multi-omics, Digital pathology.*

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and the source are properly cited.

1. Introduction

Cancer is a biologically dynamic disease characterized by continuous genomic evolution, epigenetic remodeling, immune adaptation, metabolic reprogramming, angiogenesis, tissue remodeling, and intricate interactions among malignant cells, stromal components, immune populations, and host physiology. These interconnected biological processes evolve throughout diagnosis, treatment, recurrence, metastasis, and survivorship, making precision oncology increasingly dependent upon computational systems capable of integrating heterogeneous biomedical information across multiple biological scales.[2]

Modern oncology generates enormous quantities of biomedical information through radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory

Paper Available at: *www.ijarai.com*
DOI : https://doi.org/10.65713/ijaraiv14i1223

Volume 14, Issue-12
December, 2024, P23
ISSN: 2319-9253

investigations, circulating tumor DNA, wearable physiological monitoring, physician documentation, electronic health records, and patient-reported outcomes. Although each modality contributes valuable biological insight, isolated interpretation frequently overlooks causal biological mechanisms governing disease progression, therapeutic response, resistance mechanisms, and long-term clinical outcomes.[3]

Artificial intelligence has emerged as a transformative computational technology capable of integrating these heterogeneous biomedical datasets into unified patient-centered representations. However, conventional AI frequently identifies statistical associations without distinguishing true biological causality. Causal artificial intelligence addresses this limitation by explicitly modeling cause-and-effect relationships that support trustworthy clinical reasoning and personalized therapeutic decision-making.

The convergence of causal inference, foundation AI models, and explainable computational reasoning therefore establishes a transformative framework for next-generation precision oncology.[4]

2. Evolution from Correlation-Based AI to Causal Intelligence

Artificial intelligence in oncology has evolved from conventional statistical analyses toward intelligent computational ecosystems capable of learning from multimodal biomedical information. Early machine learning algorithms primarily relied upon correlation-based predictive models developed for isolated diagnostic or prognostic applications. Although these systems demonstrated important clinical value, they frequently failed to distinguish causal biological mechanisms from coincidental statistical relationships.[5]

Deep learning substantially expanded computational capabilities through automated representation learning from radiological imaging, digital pathology, genomic sequencing, and electronic health records. Transformer architectures further revolutionized biomedical artificial intelligence by enabling generalized contextual learning across heterogeneous biomedical modalities.

Recent integration of structural causal models, Bayesian causal networks, causal discovery algorithms, reinforcement learning, foundation AI models, multimodal large language models, and digital twins has transformed computational oncology toward explainable systems capable of identifying causal pathways supporting individualized clinical decision-making.[6]

3. Principles of Causal Artificial Intelligence

Causal artificial intelligence differs fundamentally from conventional machine learning because it explicitly models cause-and-effect relationships rather than relying solely upon statistical association. Foundation AI models integrate radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, wearable physiological monitoring, physician documentation, patient-reported outcomes, and longitudinal clinical trajectories into unified computational representations capable of supporting causal reasoning.[7]

Structural causal models represent biological variables and directed causal relationships through interpretable graphical frameworks, while graph neural networks characterize interactions among genes, proteins, signaling pathways, immune populations, imaging phenotypes, tissue architecture, therapeutic targets, physiological variables, environmental exposures, and clinical outcomes.

These computational principles enable identification of causal drivers of tumor progression, therapeutic response, toxicity, recurrence, and survival while supporting transparent clinical reasoning throughout precision oncology.[8]

4. Computational Architecture

Modern causal AI platforms consist of interconnected computational layers responsible for biomedical data acquisition, preprocessing, representation learning, causal graph construction, multimodal fusion, causal inference, adaptive learning, predictive analytics, digital twin

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1223

Volume 14, Issue-12
December, 2024, P23
ISSN: 2319-9253

simulation, and intelligent clinical decision support.[9]

The acquisition layer continuously integrates radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, metabolomics, epigenomics, spatial biology, laboratory investigations, circulating tumor DNA, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, and electronic health records. Advanced preprocessing pipelines normalize imaging studies, harmonize molecular datasets, encode clinical narratives using natural language processing, and synchronize temporal patient information.

Foundation AI models subsequently generate generalized multimodal embeddings representing molecular biology, tissue architecture, imaging phenotypes, physiological function, and longitudinal clinical trajectories. Structural causal reasoning modules then identify biologically plausible causal pathways linking multimodal variables with clinically meaningful outcomes while supporting explainable precision oncology.[10]

5. Causal Intelligence for Precision Diagnosis

Early and accurate diagnosis remains one of the most important determinants of successful cancer treatment. Causal artificial intelligence substantially improves diagnostic reasoning by integrating radiological imaging, digital pathology, laboratory biomarkers, circulating tumor DNA, genomic profiling, and electronic health records into unified computational frameworks capable of identifying causal biological abnormalities associated with tumor initiation and progression.[11]

Unlike conventional correlation-based algorithms, causal AI distinguishes imaging biomarkers that directly influence disease progression from variables that merely correlate with diagnostic outcomes. Structural causal models identify pathways linking genomic alterations, tissue morphology, physiological changes, and imaging phenotypes with malignant transformation while minimizing confounding bias.

These causal computational explanations strengthen diagnostic reliability, improve generalizability across healthcare populations, and enhance clinician confidence.[12]

6. Causal Multi-Omics Intelligence

Comprehensive molecular characterization represents one of the greatest strengths of causal artificial intelligence in oncology. AI integrates genomics, transcriptomics, proteomics, metabolomics, epigenomics, immunomics, microbiomics, spatial biology, and single-cell sequencing into generalized molecular representations capable of identifying causal biological mechanisms underlying evolving tumor behavior.[13]

Transformer architectures identify latent biological relationships among genes, proteins, signaling pathways, metabolites, immune responses, and therapeutic targets, while causal graphical models distinguish mechanistic regulatory pathways from coincidental molecular associations. These computational frameworks identify driver mutations, causal biomarkers, therapeutic resistance mechanisms, and clinically actionable molecular pathways.

Consequently, causal molecular intelligence substantially improves biomarker discovery, molecular subtype classification, therapeutic response prediction, and translational oncology research.[14]

7. Explainable Radiology and Digital Pathology

Radiological imaging and digital pathology provide complementary information describing cancer biology across macroscopic and microscopic organizational scales. Foundation AI models automatically extract generalized radiomic and pathomic representations from computed tomography, magnetic resonance imaging, positron emission tomography, ultrasound, and whole-slide pathology images without requiring handcrafted feature engineering.[15]

Causal artificial intelligence distinguishes tissue features that causally influence therapeutic response or prognosis from imaging characteristics representing secondary manifestations of disease. Explainable causal frameworks identify histopathological structures, immune infiltration, angiogenesis, fibrosis,

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1223

Volume 14, Issue-12
December, 2024, P23
ISSN: 2319-9253

necrosis, and cellular morphology directly contributing to individualized clinical outcomes.
Integration of causal imaging intelligence with molecular biology substantially improves diagnosis, prognostic prediction, biomarker discovery, therapeutic optimization, and longitudinal disease monitoring.[16]

8. Clinical Intelligence Through Causal Reasoning

Electronic health records provide one of the richest longitudinal sources of clinical intelligence available in oncology. Structured laboratory investigations, medication history, pathology reports, treatment timelines, physician documentation, hospitalizations, patient-reported outcomes, and survivorship information collectively provide comprehensive patient-level context extending beyond molecular diagnostics.[17]
Foundation AI models employ natural language processing, temporal transformers, causal graphical models, and multimodal reasoning architectures to integrate structured and unstructured clinical information with radiology, pathology, molecular biology, laboratory biomarkers, and physiological monitoring into unified patient-specific computational representations.
These causal clinical embeddings identify the patient characteristics, interventions, laboratory variables, and therapeutic pathways that directly influence individualized outcomes while supporting transparent evidence-based clinical decision-making.[18]

9. Causal Therapeutic Optimization

One of the most clinically significant applications of causal artificial intelligence is individualized therapeutic optimization through explicit modeling of causal relationships linking molecular biology, imaging phenotypes, histopathological characteristics, laboratory biomarkers, physiological monitoring, medication history, and longitudinal clinical trajectories with therapeutic outcomes. Foundation AI models distinguish causal treatment effects from confounding influences while predicting responsiveness to chemotherapy, targeted therapy, endocrine therapy, immunotherapy, radiation therapy, surgery, and multimodal treatment combinations. These causal computational frameworks establish a trustworthy foundation for personalized therapeutic decision-making, improving explainability, clinical confidence, and precision oncology throughout the cancer care continuum.[19][20]

10. Causal Digital Twins and Virtual Patient Modeling

Digital twin technology represents one of the most transformative applications of causal artificial intelligence by creating continuously evolving virtual representations of individual cancer patients synchronized with their biological counterparts. Foundation AI models integrate serial radiological imaging, digital pathology, genomics, transcriptomics, proteomics, metabolomics, laboratory biomarkers, circulating tumor DNA, wearable physiological monitoring, medication history, patient-reported outcomes, and longitudinal clinical information into adaptive computational patient models capable of simulating disease progression, therapeutic response, treatment-related toxicity, recurrence, metastatic dissemination, and survival.[21]
Unlike conventional predictive models, causal digital twins explicitly distinguish causal biological mechanisms from coincidental statistical associations when simulating alternative therapeutic strategies. Structural causal models enable virtual interventions that estimate how modifying treatment variables may influence disease progression while accounting for confounding factors. These intelligent virtual patients allow clinicians to evaluate therapeutic alternatives before implementation, optimize treatment sequencing, anticipate mechanisms of therapeutic resistance, and personalize supportive care according to evolving patient biology.
By combining multimodal biomedical intelligence with causal reasoning and predictive simulation, digital twins transform computational oncology from retrospective analysis toward proactive and explainable precision medicine.

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1223

Volume 14, Issue-12
December, 2024, P23
ISSN: 2319-9253

11. Intelligent Clinical Decision Support

Causal artificial intelligence provides the computational infrastructure for next-generation clinical decision-support systems capable of integrating heterogeneous biomedical information into comprehensive patient-centered recommendations. Rather than interpreting radiological imaging, digital pathology, molecular diagnostics, laboratory investigations, wearable physiological monitoring, medication history, physician documentation, patient-reported outcomes, and evidence-based clinical guidelines independently, causal AI synthesizes these diverse biomedical information sources into unified computational representations supporting multidisciplinary oncology practice.[22]

Interactive clinical dashboards generate individualized diagnostic summaries, multimodal biomarker analyses, causal pathway visualizations, digital twin simulations, therapeutic recommendations, toxicity estimates, recurrence probabilities, disease progression forecasts, and survival predictions while explicitly identifying the biological mechanisms underlying each recommendation. These transparent systems facilitate collaboration among oncologists, radiologists, pathologists, surgeons, radiation oncologists, molecular biologists, pharmacists, nurses, genetic counselors, and computational scientists while improving workflow efficiency and evidence-based clinical decision-making.

12. Continuous Learning and Adaptive Causal Intelligence

A defining characteristic of causal artificial intelligence is its ability to continuously evolve as new biomedical information becomes available while maintaining biologically meaningful causal reasoning. Artificial intelligence incorporates serial imaging examinations, computational pathology, circulating tumor DNA, laboratory biomarkers, wearable physiological monitoring, medication adherence, patient-reported outcomes, and real-world clinical evidence into adaptive computational frameworks capable of continuously refining causal models throughout the patient's clinical journey.[23]

Continual learning algorithms enable incremental refinement of computational knowledge without catastrophic forgetting of previously acquired information, while reinforcement learning optimizes therapeutic recommendations through iterative evaluation of treatment outcomes. Causal discovery algorithms further identify newly emerging biological relationships and distinguish genuine mechanistic pathways from transient statistical correlations.

This adaptive computational paradigm transforms oncology into a continuously learning healthcare ecosystem capable of supporting trustworthy real-time precision medicine.

13. Federated Causal AI Networks

Development of highly generalizable causal AI models requires access to diverse biomedical datasets representing multiple healthcare systems, imaging platforms, pathology laboratories, molecular technologies, treatment protocols, and patient populations. Federated learning enables collaborative development of causal foundation AI models while preserving patient privacy and institutional governance through decentralized computational training.[24]

Participating healthcare institutions independently train local causal models using radiological imaging, digital pathology, genomics, transcriptomics, laboratory investigations, wearable monitoring, liquid biopsy, electronic health records, and longitudinal clinical records while securely exchanging encrypted model parameters rather than identifiable patient information. This collaborative learning strategy substantially improves algorithm robustness, fairness, external validity, transparency, and causal generalizability across diverse healthcare environments.

Federated causal AI ecosystems therefore establish international computational oncology networks capable of accelerating scientific discovery while maintaining responsible biomedical data stewardship.

14. Validation, Regulation, and Ethical Governance

Successful implementation of causal artificial intelligence requires transparent, reproducible, rigorously validated, and clinically trustworthy computational systems capable of supporting

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1223

Volume 14, Issue-12
December, 2024, P23
ISSN: 2319-9253

clinician confidence, patient trust, and regulatory approval. Explainable artificial intelligence employs attention visualization, saliency maps, SHAP (Shapley Additive Explanations), feature attribution analysis, uncertainty estimation, structural causal graphs, mediation analysis, and counterfactual reasoning to identify the imaging, molecular, pathological, physiological, and clinical variables responsible for predictive outputs while distinguishing causal pathways from simple statistical associations.[25]

Clinical deployment additionally requires standardized multimodal datasets, interoperable computational infrastructure, prospective multicenter validation, external benchmarking, cybersecurity safeguards, continuous monitoring for algorithmic bias, and compliance with evolving international regulatory frameworks governing AI-enabled healthcare technologies.

Responsible implementation further depends upon patient privacy, informed consent, transparency, accountability, equitable access, responsible data governance, continuous post-deployment surveillance, and multidisciplinary oversight to ensure trustworthy integration of causal AI into routine oncology practice.

15. Future Perspectives

Future causal oncology ecosystems will increasingly integrate multimodal foundation models, multimodal large language models, agentic artificial intelligence, graph neural networks, reinforcement learning, federated learning, digital twins, spatial multi-omics, liquid biopsy, quantum computing, Internet of Medical Things (IoMT), robotics, cloud-native healthcare infrastructure, and autonomous causal reasoning systems into unified precision oncology platforms.[26]

These next-generation computational ecosystems will continuously integrate molecular biology, radiological imaging, digital pathology, laboratory medicine, wearable physiological monitoring, environmental exposures, electronic health records, biomedical literature, and real-world clinical outcomes while autonomously identifying causal biological mechanisms, optimizing therapeutic strategies, supporting adaptive clinical trials, generating personalized patient communication, and continuously synthesizing biomedical evidence.

Such intelligent causal ecosystems are expected to transform oncology from correlation-driven prediction toward mechanistically informed, explainable, predictive, preventive, adaptive, and precision-guided healthcare.

16. Discussion

Causal artificial intelligence represents one of the most significant paradigm shifts in computational oncology by integrating foundation AI models, structural causal reasoning, radiological imaging, digital pathology, multi-omics, laboratory biomarkers, digital twins, wearable technologies, and longitudinal clinical intelligence into transparent computational ecosystems capable of supporting comprehensive personalized cancer care. Unlike conventional artificial intelligence systems developed primarily for correlation-based prediction, causal AI simultaneously analyzes multimodal biomedical information while identifying mechanistic biological pathways responsible for disease progression, therapeutic response, toxicity, and clinical outcomes.[27]

Applications spanning computational pathology, radiogenomics, biomarker discovery, digital twins, precision immunotherapy, adaptive therapeutics, causal biomarker identification, continuous learning, federated collaboration, digital health, survivorship management, and intelligent clinical decision support demonstrate the extraordinary potential of causal artificial intelligence to redefine future oncology. Nevertheless, successful implementation requires continued advances in causal discovery algorithms, multimodal data harmonization, explainable artificial intelligence, interoperability, computational infrastructure, cybersecurity, regulatory science, ethical governance, and sustained multidisciplinary collaboration.

As biomedical knowledge and healthcare data continue to expand exponentially, causal artificial intelligence is expected to become one of the foundational computational frameworks supporting trustworthy precision oncology worldwide.

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1223

Volume 14, Issue-12
December, 2024, P23
ISSN: 2319-9253

17. Conclusion

Causal artificial intelligence is transforming precision oncology by integrating foundation AI models, structural causal reasoning, radiological imaging, digital pathology, multi-omics, laboratory biomarkers, wearable technologies, electronic health records, digital twins, and longitudinal clinical intelligence into transparent computational ecosystems capable of supporting accurate diagnosis, biomarker discovery, prognostic prediction, therapeutic optimization, adaptive disease monitoring, and individualized clinical decision-making throughout the cancer care continuum.[28]

Advances in transformer architectures, multimodal learning, graph neural networks, causal inference, self-supervised learning, federated learning, reinforcement learning, digital twins, multimodal large language models, agentic AI, and generative artificial intelligence are expected to further strengthen causal oncology ecosystems, enabling increasingly accurate molecular characterization, mechanistically informed clinical intelligence, adaptive therapeutics, continuous disease surveillance, and continuously personalized cancer care while maintaining transparency and clinical trust.[29]

Although important scientific, technical, ethical, regulatory, and implementation challenges remain, sustained collaboration among oncologists, radiologists, pathologists, molecular biologists, biomedical engineers, computer scientists, healthcare organizations, policymakers, industry partners, and regulatory agencies will accelerate the responsible implementation of causal artificial intelligence in oncology. These innovations have the potential to improve patient outcomes, enhance healthcare efficiency, reduce disparities in cancer care, accelerate translational research, and establish a new era of intelligent, explainable, adaptive, and causally informed precision oncology worldwide.[30]

References

1. Meric-Bernstam, F. et al. (2023) ‘Enhancing Precision Oncology Through Multimodal Data Integration’, Nature Reviews Clinical Oncology, 20(4), pp. 267-283.
2. Dr. Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/325, DOI: https://doi.org/10.46121/pspc.52.4.14
3. Dr. RajathaMaradiHemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/343 , DOI: https://doi.org/10.46121/pspc.52.4.16
4. Joshi, A. et al. (2023) ‘Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis’, npj Precision Oncology, 7(1), p. 28.
5. Dr. Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: https://pspac.info/index.php/dlbh/article/view/312 , DOI: https://doi.org/10.46121/pspc.52.4.13.
6. Huang, S.C. et al. (2020) ‘Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review’, npj Digital Medicine, 3(1), p. 136.
7. Dr. RajathaMaradiHemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8
8. Lambin, P. et al. (2017) ‘Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis’, European Journal of Cancer, 48(4), pp. 441-446.

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1223

Volume 14, Issue-12
December, 2024, P23
ISSN: 2319-9253

9. Zwanenburg, A. et al. (2023) 'The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping', Radiology, 308(2), e221422.
10. Chen, R.J. et al. (2023) 'Towards a General-Purpose Foundation Model for Computational Pathology', Nature Medicine, 29(4), pp. 850-862.
11. Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.
12. Chaudhary, K. et al. (2021) 'Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer', Clinical Cancer Research, 27(5), pp. 1248-1259.
13. Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.
14. Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.
15. Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', Nature, 616(7956), pp. 259-265.
16. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. Doi:10.1158/2159-8290.CD-21-1059.
17. Singhal K, Azizi S, Tu T, et al. Large language models encode clinical knowledge. Nature. 2023;620(7972):172–180. Doi:10.1038/s41586-023-06291-2.
18. Xu H, Usuyama N, Bagga J, et al. A whole-slide foundation model for digital pathology from real-world data. Nature. 2024;630(8015):181–188. Doi:10.1038/s41586-024-07441-w.
19. Moor M, Banerjee O, Abad ZSH, et al. Foundation models for generalist medical artificial intelligence. Nature. 2023;616(7956):259–265. Doi:10.1038/s41586-023-05881
20. Bommasani R, Hudson DA, Adeli E, et al. On the opportunities and risks of foundation models. arXiv. 2021. Doi:10.48550/arXiv.2108.07258.
21. Dosovitskiy A, Beyer L, Kolesnikov A, et al. An image is worth 16×16 words: transformers for image recognition at scale. arXiv. 2020. Doi:10.48550/arXiv.2010.11929.
22. Dr. Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4
23. Dr. Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7
24. Chakraborty, S. et al. (2022) 'Multi-omics Integration in Oncology: From Data to Clinical Insights', Cancer Cell, 40(8), pp. 805-823.
25. Dr. Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5
26. Dr. Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/303 , DOI: https://doi.org/10.46121/pspc.52.1.5
27. Dr. Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415,

Paper Available at: www.ijarai.com
DOI : https://doi.org/10.65713/ijaraiv14i1223

https://pspac.info/index.php/dlbh/article/view/324 , DOI: https://doi.org/10.46121/pspc.52.2.14

28. Dr. Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/311, DOI: https://doi.org/10.46121/pspc.52.2.12

29. Dr. RajathaMaradiHemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April–June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/345 , DOI: https://doi.org/10.46121/pspc.52.2.18

30. Dr. RajathaMaradiHemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388 , DOI: https://doi.org/10.46121/pspc.51.4.7